Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jul;38(7):1664–1667. doi: 10.1128/aac.38.7.1664

Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus at a university hospital.

M C Layton 1, J E Patterson 1
PMCID: PMC284613  PMID: 7979305

Abstract

Mupirocin resistance was determined in consecutive oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus clinical isolates collected over 14 months at a university hospital during 1991 and 1992. Twenty of 86 (23%) oxacillin-resistant and borderline oxacillin-resistant S. aureus isolates were mupirocin resistant; 80% were high-level resistant. Prior mupirocin use was a significant risk factor (relative risk, 6.08; 95% confidence interval, 3.7 to 9.99). Seven of 20 resistant isolates were distinct strains, as determined by pulsed-field gel electrophoresis typing. Two instances of clonal dissemination of a single strain occurred, but several other distinct mupirocin-resistant strains were documented. Mupirocin resistance was unexpectedly common among these isolates.

Full text

PDF
1664

Images in this article

1666Image
on p.1666

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer G. L., Pennell E. Detection of methicillin resistance in staphylococci by using a DNA probe. Antimicrob Agents Chemother. 1990 Sep;34(9):1720–1724. doi: 10.1128/aac.34.9.1720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barrett S. P. The value of nasal mupirocin in containing an outbreak of methicillin-resistant Staphylococcus aureus in an orthopaedic unit. J Hosp Infect. 1990 Feb;15(2):137–142. doi: 10.1016/0195-6701(90)90122-5. [DOI] [PubMed] [Google Scholar]
  3. Boelaert J. R., De Baere Y. A., Geernaert M. A., Godard C. A., Van Landuyt H. W. The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness. J Hosp Infect. 1991 Sep;19 (Suppl B):41–46. doi: 10.1016/0195-6701(91)90202-j. [DOI] [PubMed] [Google Scholar]
  4. Breneman D. L. Use of mupirocin ointment in the treatment of secondarily infected dermatoses. J Am Acad Dermatol. 1990 May;22(5 Pt 1):886–892. doi: 10.1016/0190-9622(90)70119-3. [DOI] [PubMed] [Google Scholar]
  5. Capobianco J. O., Doran C. C., Goldman R. C. Mechanism of mupirocin transport into sensitive and resistant bacteria. Antimicrob Agents Chemother. 1989 Feb;33(2):156–163. doi: 10.1128/aac.33.2.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Casewell M. W., Hill R. L. Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid')--a controlled trial. J Antimicrob Chemother. 1986 Mar;17(3):365–372. doi: 10.1093/jac/17.3.365. [DOI] [PubMed] [Google Scholar]
  7. Casewell M. W., Hill R. L. In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1985 May;15(5):523–531. doi: 10.1093/jac/15.5.523. [DOI] [PubMed] [Google Scholar]
  8. Casewell M. W., Hill R. L. Mupirocin ('pseudomonic acid')--a promising new topical antimicrobial agent. J Antimicrob Chemother. 1987 Jan;19(1):1–5. doi: 10.1093/jac/19.1.1. [DOI] [PubMed] [Google Scholar]
  9. Cookson B. D., Lacey R. W., Noble W. C., Reeves D. S., Wise R., Redhead R. J. Mupirocin-resistant Staphylococcus aureus. Lancet. 1990 May 5;335(8697):1095–1096. doi: 10.1016/0140-6736(90)92667-7. [DOI] [PubMed] [Google Scholar]
  10. Dacre J. E., Emmerson A. M., Jenner E. A. Nasal carriage of gentamicin and methicillin resistant Staphylococcus aureus treated with topical pseudomonic acid. Lancet. 1983 Oct 29;2(8357):1036–1036. doi: 10.1016/s0140-6736(83)91029-2. [DOI] [PubMed] [Google Scholar]
  11. Dyke K. G., Curnock S. P., Golding M., Noble W. C. Cloning of the gene conferring resistance to mupirocin in Staphylococcus aureus. FEMS Microbiol Lett. 1991 Jan 15;61(2-3):195–198. doi: 10.1016/0378-1097(91)90550-t. [DOI] [PubMed] [Google Scholar]
  12. Forbes B. A., Schaberg D. R. Transfer of resistance plasmids from Staphylococcus epidermidis to Staphylococcus aureus: evidence for conjugative exchange of resistance. J Bacteriol. 1983 Feb;153(2):627–634. doi: 10.1128/jb.153.2.627-634.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fuchs P. C., Jones R. N., Barry A. L. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic. J Clin Microbiol. 1990 Mar;28(3):608–609. doi: 10.1128/jcm.28.3.608-609.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hill R. L., Casewell M. W. Nasal carriage of MRSA: the role of mupirocin and outlook for resistance. Drugs Exp Clin Res. 1990;16(8):397–402. [PubMed] [Google Scholar]
  15. Hill R. L., Casewell M. W. Reduction in the colonization of central venous cannulae by mupirocin. J Hosp Infect. 1991 Sep;19 (Suppl B):47–57. doi: 10.1016/0195-6701(91)90203-k. [DOI] [PubMed] [Google Scholar]
  16. Hill R. L., Duckworth G. J., Casewell M. W. Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak. J Antimicrob Chemother. 1988 Sep;22(3):377–384. doi: 10.1093/jac/22.3.377. [DOI] [PubMed] [Google Scholar]
  17. Hill R. L., Fisher A. P., Ware R. J., Wilson S., Casewell M. W. Mupirocin for the reduction of colonization of internal jugular cannulae--a randomized controlled trial. J Hosp Infect. 1990 May;15(4):311–321. doi: 10.1016/0195-6701(90)90088-6. [DOI] [PubMed] [Google Scholar]
  18. Hughes J., Mellows G. On the mode of action of pseudomonic acid: inhibition of protein synthesis in Staphylococcus aureus. J Antibiot (Tokyo) 1978 Apr;31(4):330–335. doi: 10.7164/antibiotics.31.330. [DOI] [PubMed] [Google Scholar]
  19. Kauffman C. A., Terpenning M. S., He X., Zarins L. T., Ramsey M. A., Jorgensen K. A., Sottile W. S., Bradley S. F. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am J Med. 1993 Apr;94(4):371–378. doi: 10.1016/0002-9343(93)90147-h. [DOI] [PubMed] [Google Scholar]
  20. Layton M. C., Perez M., Heald P., Patterson J. E. An outbreak of mupirocin-resistant Staphylococcus aureus on a dermatology ward associated with an environmental reservoir. Infect Control Hosp Epidemiol. 1993 Jul;14(7):369–375. doi: 10.1086/646764. [DOI] [PubMed] [Google Scholar]
  21. Maple P. A., Hamilton-Miller J. M., Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet. 1989 Mar 11;1(8637):537–540. doi: 10.1016/s0140-6736(89)90076-7. [DOI] [PubMed] [Google Scholar]
  22. McLinn S. A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J Am Acad Dermatol. 1990 May;22(5 Pt 1):883–885. doi: 10.1016/0190-9622(90)70118-2. [DOI] [PubMed] [Google Scholar]
  23. Moy J. A., Caldwell-Brown D., Lin A. N., Pappa K. A., Carter D. M. Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J Am Acad Dermatol. 1990 May;22(5 Pt 1):893–895. doi: 10.1016/0190-9622(90)70120-7. [DOI] [PubMed] [Google Scholar]
  24. Noble W. C., Rahman M., Cookson B., Phillips I. Transferable mupirocin-resistance. J Antimicrob Chemother. 1988 Nov;22(5):771–772. doi: 10.1093/jac/22.5.771-a. [DOI] [PubMed] [Google Scholar]
  25. Rahman M., Connolly S., Noble W. C., Cookson B., Phillips I. Diversity of staphylococci exhibiting high-level resistance to mupirocin. J Med Microbiol. 1990 Oct;33(2):97–100. doi: 10.1099/00222615-33-2-97. [DOI] [PubMed] [Google Scholar]
  26. Rahman M., Noble W. C., Cookson B. Transmissible mupirocin resistance in Staphylococcus aureus. Epidemiol Infect. 1989 Apr;102(2):261–270. doi: 10.1017/s0950268800029939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Reagan D. R., Doebbeling B. N., Pfaller M. A., Sheetz C. T., Houston A. K., Hollis R. J., Wenzel R. P. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med. 1991 Jan 15;114(2):101–106. doi: 10.7326/0003-4819-114-2-101. [DOI] [PubMed] [Google Scholar]
  28. Smith G. E., Kennedy C. T. Staphylococcus aureus resistant to mupirocin. J Antimicrob Chemother. 1988 Jan;21(1):141–142. doi: 10.1093/jac/21.1.141. [DOI] [PubMed] [Google Scholar]
  29. Wise R., Johnson J. Mupirocin resistance. Lancet. 1991 Aug 31;338(8766):578–578. doi: 10.1016/0140-6736(91)91148-n. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES